Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors by Tal Sella, Yue Zheng, Shoshana M. Rosenberg, Kathryn J. Ruddy, Shari I. Gelber, Rulla M. Tamimi, Jeffrey M. Peppercorn, Lidia Schapira, Virginia F. Borges, Steven E. Come, Lisa A. Carey, Eric P. Winer, Ann H. Partridge

Get full text

Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis by Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman, Einav Nili Gal-Yam

Get full text

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT) by Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J. Ruddy, Rachel A. Freedman, Chau Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Michelle DeMeo, Harold J. Burstein, Eric P. Winer, Antonio C. Wolff, Ian Krop, Ann H. Partridge, Sara M. Tolaney

Get full text